Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Name: Kaimen Rigor review — Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.
Item: Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.
Rating: 96
Author: Alpha1

Steel JL, George CJ, Terhorst L, Yabes JG, Reyes V, Zandberg DP, Nilsen M, Kiefer G, Johnson J, Marsh C, Bierenbaum J, Tageja N, Krauze M, VanderWeele R, Goel G, Ramineni G, Antoni M, Vodovotz Y, Walker J, Tohme S, Billiar T, Geller DA

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)00015-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0d2e799e-958a-4c20-aa0e-d1822f5c0cf2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0d2e799e-958a-4c20-aa0e-d1822f5c0cf2/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

520f003a344e457241ad2495f91c8a91c7cc7bb3528556212865afe98da810ff

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Paper source

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is health-related quality of life (HRQOL) measured by the FACT-General, which is a patient-reported outcome. While HRQOL is a clinical outcome, it is a surrogate for more definitive outcomes like survival or disease progression. The paper does not provide evidence linking improvements in HRQOL to hard clinical outcomes, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD) for the intervention. The efficacy claim is based on a surrogate measure without a validated link to clinical benefit.
“The primary outcome was health-related quality of life in patients at 6 months.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size for the primary outcome (HRQOL) is small (Cohen's d = 0.09 for between-group difference at 6 months). The paper claims this is clinically meaningful, but the effect size is below the commonly accepted threshold for a minimal clinically important difference (MCID) for HRQOL measures. No anchor to clinical meaningfulness is provided beyond the authors' assertion.
“Patients in the stepped collaborative care group had a greater 0–6-month improvement in health-related quality of life than patients in the standard-of-care group (p=0·013, effect size 0·09).”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The intervention is cost-saving and could shift practice.
“The findings of this study will advance the implementation of guideline concordant care (screening and treatment) and has the potential to shift the practice of screening and treatment paradigm nationwide, improving outcomes for patients diagnosed with cancer.”
InterpretationFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized phase 3 trial with rigorous design, clear ethics approval, and appropriate statistical methods. The main weakness is the vague data sharing statement, which lacks a concrete access mechanism or repository deposit. Minor copyedit issues and an overstated claim about shifting practice nationwide are also noted.

Both reviewers independently scored all eight dimensions and agreed on all statuses, so no divergence needed reconciliation. The study is interventional (randomized controlled trial). Non-applicable criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests; the rest were not machine-verifiable, so statistical correctness is not fully confirmed.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on cancer-related symptoms, the ineffectiveness of standard screening and referral, and the evidence base for collaborative care. It acknowledges limitations of prior work (e.g., only one UK study showing cost-effectiveness, guidelines not integrating screening and treatment) and explains how the current study addresses these gaps. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“Decades of research have shown the effectiveness and cost-effectiveness of the collaborative care approach, which is widely implemented across primary care practices in the USA.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

“Although these advancements are important, the guidelines do not include integration of screening and treatment, thereby not solving the problem with initiation of treatment following screening.”

“This study aimed to test the efficacy of an integrated screening and novel stepped collaborative care intervention versus standard of care (ie, screening and treatment referral) for patients with cancer and comorbid symptoms, such as depression, pain, and fatigue.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“Decades of research have shown the effectiveness and cost-effectiveness of the collaborative care approach, which is widely implemented across primary care practices in the USA.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

IntroductionFind in source

Randomization used a central permuted block design stratified by sex and prognostic status. Masking of biostatisticians, oncologists, and outcome assessors was described. A priori power analysis was provided with effect sizes and sample size calculations. Inclusion/exclusion criteria were pre-specified. Outlier handling is addressed through intention-to-treat analysis and sensitivity analyses for missing data. Controls are inherent in the standard-of-care comparator. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, masking, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“Patients were randomly assigned (1:1) to stepped collaborative care or standard of care using a central, permuted block design (sizes of 2, 4, and 6) stratified by sex (male or female) and prognostic status.”

“The biostatisticians, oncologists, and outcome assessors were masked to patient allocation until 12-month outcome data were collected.”

MethodsFind in source

“a sample size of 364 (182 participants per group) would have 80% power to detect a between-group effect (Cohen’s d ) as small as 0·15 and 95% power to detect a within-group effect (Cohen’s d ) as small as 0·10.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, masking, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“The biostatisticians, oncologists, and outcome assessors were masked to patient allocation until 12-month outcome data were collected.”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for patients and caregivers. Age and health status (cancer type, stage, comorbidities) are reported. Demographics include race, education, income, and marital status. Since both sexes are enrolled, sex justification is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Patient demographics and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Patients’ mean age was 65·70 years (SD 11·42), and of 459 patients, 201 (44%) were male and 258 (56%) were female.”

Results ¶1Find in source

“White | 218 (92%) | 207 (93%) | 95 (96%) | 85 (93%)”

Table 1Find in source

“Stage IV | 105 (44%) | 86 (39%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Patient demographics and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Patients’ mean age was 65·70 years (SD 11·42), and of 459 patients, 201 (44%) were male and 258 (56%) were female.”

Results ¶1Find in source

paraphrase[Table 1]

“Ethnicity | White | 218 (92%) | 207 (93%) | 95 (96%) | 85 (93%)”

paraphrase[Table 1]

“Cancer diagnosis | Liver | 54 (23%) | 55 (25%)”

The study received approval from the University of Pittsburgh Institutional Review Board with a protocol number (PRO15030290). Written informed consent was obtained from patients. Regulatory compliance is implied through IRB approval and adherence to ethical standards, though not explicitly naming a framework like the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from a named IRB and informed consent are clearly documented.

Evidence

“Ethics approval was received from the University of Pittsburgh Institutional Review Board (PRO15030290).”

MethodsFind in source

“Patients provided written informed consent.”

MethodsFind in source

absence[Methods]

No explicit statement of compliance with a specific regulatory framework.

PASSReviewer 2· 95% conf

Ethics approval from a named IRB and informed consent are clearly documented.

Evidence

“Ethics approval was received from the University of Pittsburgh Institutional Review Board (PRO15030290).”

MethodsFind in source

“Patients provided written informed consent.”

MethodsFind in source

The intervention is described with details on delivery, frequency, and content. Pharmacotherapy is mentioned but not specified as a named drug. Statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or organisms are used, so those criteria are not applicable. The intervention itself is the key resource and is adequately described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational intervention (CBT and pharmacotherapy) is described in detail, and software tools are identified.

Evidence

“The stepped collaborative care intervention was once weekly CBT for approximately 50–60 min from a care coordinator based on the patients’ preference for treatment (eg, psychotherapy, pharmacotherapy) and delivery (eg, telephone or videoconferencing).”

MethodsFind in source

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational intervention (CBT and pharmacotherapy) is described in detail, and the software used for analysis is identified.

Evidence

MethodsFind in source

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

The primary analysis used linear mixed effects models with details on covariance structure and degrees of freedom. Exact p-values are reported (e.g., p=0·013). Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes per-group n and error bars. Mathematical plausibility checks were not possible for all results due to complex models, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes reported.

Evidence

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

“p=0·013, effect size 0·09”

AbstractFind in source

“Error bars are 95% CI.”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes reported.

Evidence

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4) to incorporate all available data and test hypotheses”

Statistical analysisFind in source

“p=0·013, effect size 0·09”

Results ¶4Find in source

“Error bars are 95% CI.”

Figure 3Find in source

The data sharing statement says de-identified data will be available on request from the principal investigator, but does not specify a platform, conditions, or timeframe. This is reported_but_inadequate. No code sharing is mentioned, and no repository deposit or accession numbers are provided.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement exists but is vague, lacking a concrete mechanism or platform.

Evidence

“De-identified data will be available on request from the principal investigator ( steejl@upmc.edu ) to those with appropriate qualifications, approved aims and hypotheses, and a signed data access agreement.”

Data availabilityFind in source

absence[Data sharing section]

No repository deposit mentioned.

absence[Data sharing section]

No code sharing mentioned.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

Data availabilityFind in source

The trial is registered with ClinicalTrials.gov (NCT02939755). Methods are detailed enough for replication. Limitations are discussed, including COVID-19 pandemic, missing data, and generalizability. Conclusions are proportional to the evidence. Funding and conflicts of interest are declared. No reporting guideline checklist is mentioned, but this is not mandatory for a trial report.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“This trial was registered with ClinicalTrials.gov (https://clinicaltrials.gov/) ( NCT02939755 (https://clinicaltrials.gov/ct2/show/NCT02939755) ).”

Statistical analysisFind in source

“Although this study has many strengths, there were also limitations. The trial was partly conducted during the COVID-19 pandemic.”

Discussion ¶5Find in source

“JLS receives royalties from Springer for the books Living Donor Advocacy and Psychological Aspects of Cancer .”

Declaration of interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“This trial was registered with ClinicalTrials.gov (https://clinicaltrials.gov/) ( NCT02939755 (https://clinicaltrials.gov/ct2/show/NCT02939755) ).”

Statistical analysisFind in source

“The trial was partly conducted during the COVID-19 pandemic. Sensitivity analyses were performed to test outcomes for patients who were treated before versus during the COVID-19 pandemic (March 2020); we did not observe any differences in outcomes.”

Discussion ¶5Find in source

“JLS receives royalties from Springer for the books Living Donor Advocacy and Psychological Aspects of Cancer .”

Declaration of interestsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 30 references by DOI: 23 verified — 7 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly clarity, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported, with only minor reporting gaps. An informed reader should weigh the vague data sharing statement and the slightly overstated claim about shifting practice nationwide. No erratum is warranted, but the authors could improve transparency by depositing data in a repository and tempering the claim.

1.
HIGHdata code
In the Data sharing section, specify a concrete data access mechanism such as depositing de-identified data in a repository (e.g., Vivli, Dryad, Zenodo) with conditions and a timeframe, rather than only 'on request'.
The current vague 'on request' statement is inadequate for reproducibility and is the only major rigor gap.
2.
HIGHdata code
Add a statement about analysis code availability in the Data sharing section, either providing a link to a repository or stating that no custom code was used.
Code sharing is not mentioned, which limits reproducibility.
3.
HIGHrigor
In the Discussion, temper the claim that the intervention 'has the potential to shift the practice of screening and treatment paradigm nationwide' to reflect that this is a single-trial finding requiring replication.
The claim audit flagged this as overstated; over-claiming is a common reviewer objection.
4.
MEDIUMreporting
Add an explicit statement of compliance with the Declaration of Helsinki or other regulatory framework in the Methods/ethics section.
Reviewer 1 noted that regulatory compliance is implied but not explicitly named; adding it strengthens the ethics reporting.
5.
MEDIUMreporting
Mention adherence to the CONSORT reporting guideline in the Methods or acknowledgments.
The paper does not reference a reporting guideline, which is a minor transparency gap for a trial report.
6.
MEDIUMreporting
Clarify the specific pharmacotherapy agents used in the intervention, if any, in the Methods/Procedures section.
The intervention description mentions pharmacotherapy but does not name specific drugs, which limits replicability.
7.
MEDIUMcopyedit
In the Abstract and Results, specify the effect size type (e.g., Cohen's d) when reporting 'effect size 0·09'.
The copyedit pass flagged inconsistent effect size notation; specifying the type improves clarity.
8.
MEDIUMcopyedit
In Results, paragraph 3, clarify the term 'p difference' to 'p-value for between-group difference'.
The copyedit pass noted that 'p difference' is non-standard and could confuse readers.
9.
MEDIUMcopyedit
In Results, paragraph 3, complete the sentence 'The distribution of symptoms by treatment group is shown in the (p 5).' with the correct figure/table reference.
The copyedit pass flagged an incomplete sentence referencing supplementary material.
10.
LOWcopyedit
In Discussion, paragraph 2, split the long sentence about caregiver outcomes and CVD risk into shorter sentences for clarity.
The copyedit pass flagged the sentence as overly long and complex.
11.
LOWreporting
Clarify the role of the funder in the Role of the funding source section.
Reviewer 2 suggested clarifying funder role to ensure transparency.

Full text (51,754 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Read full text (PMC)

DOI

10.1016/S0140-6736(24)00015-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0d2e799e-958a-4c20-aa0e-d1822f5c0cf2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0d2e799e-958a-4c20-aa0e-d1822f5c0cf2/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

520f003a344e457241ad2495f91c8a91c7cc7bb3528556212865afe98da810ff

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary outcome is health-related quality of life (HRQOL) measured by the FACT-General, which is a patient-reported outcome. While HRQOL is a clinical outcome, it is a surrogate for more definitive outcomes like survival or disease progression. The paper does not provide evidence linking improvements in HRQOL to hard clinical outcomes, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD) for the intervention. The efficacy claim is based on a surrogate measure without a validated link to clinical benefit.
“The primary outcome was health-related quality of life in patients at 6 months.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size for the primary outcome (HRQOL) is small (Cohen's d = 0.09 for between-group difference at 6 months). The paper claims this is clinically meaningful, but the effect size is below the commonly accepted threshold for a minimal clinically important difference (MCID) for HRQOL measures. No anchor to clinical meaningfulness is provided beyond the authors' assertion.
“Patients in the stepped collaborative care group had a greater 0–6-month improvement in health-related quality of life than patients in the standard-of-care group (p=0·013, effect size 0·09).”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The intervention is cost-saving and could shift practice.
“The findings of this study will advance the implementation of guideline concordant care (screening and treatment) and has the potential to shift the practice of screening and treatment paradigm nationwide, improving outcomes for patients diagnosed with cancer.”
InterpretationFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

4 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“Decades of research have shown the effectiveness and cost-effectiveness of the collaborative care approach, which is widely implemented across primary care practices in the USA.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the premise to the study objectives.

Evidence

“Decades of research have shown the effectiveness and cost-effectiveness of the collaborative care approach, which is widely implemented across primary care practices in the USA.”

Introduction ¶3Find in source

paraphrase[Introduction, paragraph 4]

IntroductionFind in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, masking, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“The biostatisticians, oncologists, and outcome assessors were masked to patient allocation until 12-month outcome data were collected.”

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, masking, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomisation and masking]

“The biostatisticians, oncologists, and outcome assessors were masked to patient allocation until 12-month outcome data were collected.”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Patient demographics and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Patients’ mean age was 65·70 years (SD 11·42), and of 459 patients, 201 (44%) were male and 258 (56%) were female.”

Results ¶1Find in source

“White | 218 (92%) | 207 (93%) | 95 (96%) | 85 (93%)”

Table 1Find in source

“Stage IV | 105 (44%) | 86 (39%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Patient demographics and clinical characteristics are well reported, including sex, age, and health status.

Evidence

“Patients’ mean age was 65·70 years (SD 11·42), and of 459 patients, 201 (44%) were male and 258 (56%) were female.”

Results ¶1Find in source

paraphrase[Table 1]

“Ethnicity | White | 218 (92%) | 207 (93%) | 95 (96%) | 85 (93%)”

paraphrase[Table 1]

“Cancer diagnosis | Liver | 54 (23%) | 55 (25%)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval from a named IRB and informed consent are clearly documented.

Evidence

“Ethics approval was received from the University of Pittsburgh Institutional Review Board (PRO15030290).”

MethodsFind in source

“Patients provided written informed consent.”

MethodsFind in source

absence[Methods]

No explicit statement of compliance with a specific regulatory framework.

PASSReviewer 2· 95% conf

Ethics approval from a named IRB and informed consent are clearly documented.

Evidence

“Ethics approval was received from the University of Pittsburgh Institutional Review Board (PRO15030290).”

MethodsFind in source

“Patients provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational intervention (CBT and pharmacotherapy) is described in detail, and software tools are identified.

Evidence

MethodsFind in source

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational intervention (CBT and pharmacotherapy) is described in detail, and the software used for analysis is identified.

Evidence

MethodsFind in source

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes reported.

Evidence

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4)”

Statistical analysisFind in source

“p=0·013, effect size 0·09”

AbstractFind in source

“Error bars are 95% CI.”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes reported.

Evidence

“Linear mixed effect models were performed using SAS (PROC MIXED; version 9.4) to incorporate all available data and test hypotheses”

Statistical analysisFind in source

“p=0·013, effect size 0·09”

Results ¶4Find in source

“Error bars are 95% CI.”

Figure 3Find in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data sharing statement exists but is vague, lacking a concrete mechanism or platform.

Evidence

Data availabilityFind in source

absence[Data sharing section]

No repository deposit mentioned.

absence[Data sharing section]

No code sharing mentioned.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“This trial was registered with ClinicalTrials.gov (https://clinicaltrials.gov/) ( NCT02939755 (https://clinicaltrials.gov/ct2/show/NCT02939755) ).”

Statistical analysisFind in source

“Although this study has many strengths, there were also limitations. The trial was partly conducted during the COVID-19 pandemic.”

Discussion ¶5Find in source

“JLS receives royalties from Springer for the books Living Donor Advocacy and Psychological Aspects of Cancer .”

Declaration of interestsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“This trial was registered with ClinicalTrials.gov (https://clinicaltrials.gov/) ( NCT02939755 (https://clinicaltrials.gov/ct2/show/NCT02939755) ).”

Statistical analysisFind in source

Discussion ¶5Find in source

“JLS receives royalties from Springer for the books Living Donor Advocacy and Psychological Aspects of Cancer .”

Declaration of interestsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 30 references by DOI: 23 verified — 7 no DOI (shown, not verified).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly clarity, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data sharing section, specify a concrete data access mechanism such as depositing de-identified data in a repository (e.g., Vivli, Dryad, Zenodo) with conditions and a timeframe, rather than only 'on request'.
The current vague 'on request' statement is inadequate for reproducibility and is the only major rigor gap.
2.
HIGHdata code
Add a statement about analysis code availability in the Data sharing section, either providing a link to a repository or stating that no custom code was used.
Code sharing is not mentioned, which limits reproducibility.
3.
HIGHrigor
In the Discussion, temper the claim that the intervention 'has the potential to shift the practice of screening and treatment paradigm nationwide' to reflect that this is a single-trial finding requiring replication.
The claim audit flagged this as overstated; over-claiming is a common reviewer objection.
4.
MEDIUMreporting
Add an explicit statement of compliance with the Declaration of Helsinki or other regulatory framework in the Methods/ethics section.
Reviewer 1 noted that regulatory compliance is implied but not explicitly named; adding it strengthens the ethics reporting.
5.
MEDIUMreporting
Mention adherence to the CONSORT reporting guideline in the Methods or acknowledgments.
The paper does not reference a reporting guideline, which is a minor transparency gap for a trial report.
6.
MEDIUMreporting
Clarify the specific pharmacotherapy agents used in the intervention, if any, in the Methods/Procedures section.
The intervention description mentions pharmacotherapy but does not name specific drugs, which limits replicability.
7.
MEDIUMcopyedit
In the Abstract and Results, specify the effect size type (e.g., Cohen's d) when reporting 'effect size 0·09'.
The copyedit pass flagged inconsistent effect size notation; specifying the type improves clarity.
8.
MEDIUMcopyedit
In Results, paragraph 3, clarify the term 'p difference' to 'p-value for between-group difference'.
The copyedit pass noted that 'p difference' is non-standard and could confuse readers.
9.
MEDIUMcopyedit
In Results, paragraph 3, complete the sentence 'The distribution of symptoms by treatment group is shown in the (p 5).' with the correct figure/table reference.
The copyedit pass flagged an incomplete sentence referencing supplementary material.
10.
LOWcopyedit
In Discussion, paragraph 2, split the long sentence about caregiver outcomes and CVD risk into shorter sentences for clarity.
The copyedit pass flagged the sentence as overly long and complex.
11.
LOWreporting
Clarify the role of the funder in the Role of the funding source section.
Reviewer 2 suggested clarifying funder role to ensure transparency.

Full text (51,754 chars)Analyzed: Aug 16, 2026